Abstract
The value of morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression for prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients was evaluated in a group of CMF treated patients and controls with long-term follow-up. In the treated group, the Morphometric Prognostic Index (cutpoint 1.1) was the best prognosticator (p less than 0.0001, MC = 16.9), followed by the Mitotic Activity Index, the volume percentage epithelium and the number of positive nodes. For the controls, only the % HER-2/neu oncoprotein expression revealed significant differences (p less than 0.0001, MC = 16.3). When directly comparing treated patients and controls stratified for a certain parameter, no significant differences were obtained, although a trend towards improved survival in the treated group was present for some of the subgroups for several parameters. These preliminary results indicate that morphometric features and quantitative HER-2/neu oncoprotein expression may be important factors for identifying cases that will or will not respond to adjuvant chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 344-9 |
| Number of pages | 6 |
| Journal | Pathology |
| Volume | 188 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Apr 1992 |
Keywords
- Adult
- Breast Neoplasms
- Chemotherapy, Adjuvant
- DNA, Neoplasm
- Female
- Flow Cytometry
- Follow-Up Studies
- Humans
- Lymphatic Metastasis
- Menstruation
- Middle Aged
- Oncogene Proteins, Viral
- Predictive Value of Tests
- Receptor, ErbB-2
- Retrospective Studies
- Staining and Labeling
Fingerprint
Dive into the research topics of 'Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver